Skip to content
Review Open access

The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta-Analysis.

Jul 2026 · Andrology · 0 citations · 41 references
Medicine

TL;DR

A systematic review and meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis.

Abstract

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic-pituitary-gonadal axis. We conducted a systematic review and meta-analysis to evaluate the bidirectional association between circulating T levels and MASLD in adult men.

Methods

Following PRISMA guidelines, a literature search was performed from inception to July 31, 2025. Twenty-eight studies met the inclusion criteria (9 comparing hypogonadal vs. eugonadal men; 19 comparing MASLD vs. non-MASLD men). Random-effects models were used to pool effect sizes for dichotomous and continuous outcomes. Meta-regression analyses assessed the influence of age, anthropometric features, glycemic markers, liver enzymes, and hormonal parameters.

Results

Hypogonadal men showed a significantly higher prevalence of MASLD than eugonadal men (p = 0.001) and exhibited higher fatty liver index scores (p < 0.001). Total T concentrations were significantly lower in men with MASLD than in controls (p = 0.014). Meta-regression analyses did not identify significant effects of study-level differences in age, body mass index, or biochemical variables on the observed associations. Sex hormone-binding globulin levels were also significantly reduced in MASLD (p < 0.001), with age emerging as the only significant modifier. No significant differences were observed for luteinizing hormone, estradiol, or fibrosis-4 index. Across studies evaluating MASLD severity, moderate-to-severe disease was associated with lower T levels, particularly in analyses based on imaging.

Conclusions

This meta-analysis supports a clinically relevant association between testosterone deficiency and MASLD, although evidence for the bidirectional nature of this relationship remains asymmetric but supports a clinically relevant endocrine-hepatic axis. T deficiency appears independently linked to MASLD onset and severity beyond the effects of age and adiposity. These findings underscore the need for reciprocal screening of liver health and gonadal status in at-risk men and highlight the importance of prospective studies and randomized trials to determine whether correcting T deficiency may modify MASLD progression.

Read PDF

Similar papers

Open access Aug 2026

EP575 - ECE_1616 - Metabolic dysfunction–associated steatotic liver disease and testosterone serum levels: converging evidence from real-world observational data and meta-analysis

Low testosterone has been increasingly associated with metabolic dysfunction–associated steatotic liver disease (MASLD), yet the strength, direction, and clinical relevance of this relationship remain incompletely defined, particularly with respect to liver fibrosis. To investigate the association between...

G. Spaggiari, L. Valentina, C. Felicani et al. · 0 citations
Review Open access Aug 2026

Treatment strategies for functional hypogonadism in obese men: a systematic review and network meta-analysis.

INTRODUCTION Obesity-related functional hypogonadism (FH) is a potentially reversible condition associated with sexual dysfunction, metabolic disorders, altered body composition, and impaired quality of life. Although several treatment strategies are available, their comparative benefits and safety remain uncertain. Th...

Liang-Liang Yang, Xin-Lei He, Shi-Ze Wang et al. · 0 citations
Review Open access Sep 2026

Hypogonadism in aging men: Impact of comorbidities, diagnosis and treatment.

Male hypogonadism is increasingly prevalent with advancing age and is particularly frequent among men with obesity, type 2 diabetes mellitus, and other cardiometabolic comorbidities (functional hypogonadism), whereas it remains relatively uncommon in younger men except in the presence of congenital or acquired disorder...

Serena Anna Ravelli, E. Maseroli, Linda Vignozzi · 0 citations
Review Open access Aug 2026

Testosterone replacement therapy in metabolic dysfunction-associated steatotic liver disease: a bench-to-bedside narrative review

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with obesity, insulin resistance, and increased cardiovascular risk. Male hypogonadism has emerged as a potentially modifiable risk factor, and testosterone replacement therapy (TRT) has been proposed as a potential adjunctive treat...

Yuchang Li, Vassilios Papadopoulos · 0 citations
Open access Aug 2026

EP1363 - ECE_3272 - Central adiposity drives persistent MASLD risk in postmenopausal women with a phenotype of Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is increasingly recognised as a lifelong endocrine–metabolic condition, yet its contribution to metabolic dysfunction–associated steatotic liver disease (MASLD) beyond the reproductive years remains uncertain. Menopause is accompanied by adverse changes in fat distribution and met...

E. Armeni, Nektaria Papanikola, A. Augoulea et al. · 0 citations
Open access Aug 2026

Metabolic dysfunction in women with PCOS is more closely linked to BMI than to hyperandrogenism

Introduction Polycystic ovary syndrome (PCOS) is frequently conceptualized as a hyperandrogenic disorder, yet cardiometabolic risk may be driven primarily by obesity and insulin resistance. We characterized glucose–insulin dynamics in women with PCOS and examined whether metabolic dysfunction was more closely associate...

Paria Naderi, B. Hellwig, Lukas van Baal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.